ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer

Amy Giles
Increasing Engagement

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Brenda Snow
Authentic Patient Voice

Frank Burrell
Scientific Storytelling

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement

Matt Turner
Patient Affordability